

Methodological Note for Disclosures of Transfer of Value

Introduction

This note describes the methodology used by Leadiant Biosciences Ltd (“Leadiant”) to identify, collate and report transfers of value disclosures, in compliance with the Association of British Pharmaceutical Industry (ABPI) code. The ABPI code requires disclosures of all transfers of value to healthcare organisations (HCOs), healthcare practitioners (HCPs) and other relevant decision makers (ORDMs) in the year previous to year of disclosure. This note will report on transfers of value made in the period January 1st 2023 and December 31st, 2024. All transfers of value in Europe will be disclosed.

Definitions

Healthcare Organisation (HCO):

A healthcare, medical or scientific association or organisation (e.g., a hospital, clinic, foundation, university or other teaching institution or learned society) whose business address, place of incorporation or primary place of operation is in Europe; or an organisation through which one or more HCPs or ORDMs provide services. This can also include a personal services company.

Healthcare Professional (HCP):

A member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his/her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe.

Other relevant decision makers (ORDM):

Those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

Transfer of Value (ToV):

Direct and indirect transfers of value (in payments or kind, or otherwise made) in connection with the development or sale of prescription-only medicinal products for human use whether for promotional services or otherwise. A direct transfer of value is one made directly by Leadiant for the benefit of a recipient. An indirect transfer of value is one made by a third party on behalf of Leadiant for the benefit of a recipient where the identity of the company is known or can be identified.

Research and Development (R&D): HCO/HCP transfers of value that relate to the planning and conduct of: Non-clinical studies (as defined in OECD Principles on Good Laboratory Practice), Clinical trials (as defined in Directive 2001/20/EC), Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study. This also includes investigator sponsored research (ISRs). Non-interventional studies that are retrospective in nature have also been included within aggregate disclosure for R&D in this reporting year.

In case of differences between the EFPIA reporting definitions and the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for categorisation of transfers of value, the methodology used reflects the ABPI definitions.

Donations: Benefits in kind provided to HCOs for specified use.

Grants: Funding provided to HCOs/HCPs in response to a request to support a specific activity that provides educational benefit or enhances patient care. This includes unsolicited requests for funds and/or product for investigator-initiated research or projects for patient benefit.

Congress and educational event sponsorship: Expenses related to the sponsorship of HCOs as congress organisers in exchange for corporate benefits at an event (e.g., booth space, hosting of a symposium, stands, advertising on programs or banners and room hire or catering if paid on behalf of an HCO).

Fees: Transfers of Value which are fees paid for service resulting from or related to contracts between companies and institutions, organisations, HCPs or associations of HCPs under which such institutions, organisations or associations provide any type of services to the company or any other type of funding not covered in the previous categories.

Identification of Transfers of Value:

To identify all transfers of value, all payments for Grants, Sponsorship, Donations and Consultancy fees made in 2022 by Leadiant Biosciences UK were screened, and those fitting the requirements of transfers of value were included. These were cross-checked against the compliance approval system in the company for the period between 1st of January 2023 and 31st December, 2023.

Data Privacy

Leadiant Biosciences discloses the data on the basis of legitimate interests. Consent to disclose is included in the grant/sponsorship agreements but consent is not specifically confirmed prior to publication.

Beneficiary

Where a transfer of value is made to a healthcare professional indirectly via a healthcare organisation, where possible Leadiant aims to disclose the transfers of value made to the healthcare professional that the payment benefits, as per the ABPI code. Leadiant discloses the exact amount paid to the HCP, HCO or ORDM. This may include VAT, if VAT was included on the invoice. For transfers of value where a product is provided free of cost for research, the amount disclosed is calculated using the unit list price in the country concerned.

Currency

All transfers of value specified in our disclosure are denominated in pounds sterling. If the original payment was made in Euros, we have converted the amount into GBP using the foreign exchange rate on closing on the day of payment. Amounts disclosed in GBP may

therefore vary from the exact amount paid in the local currency.

Location

All transfers of value are disclosed on the Disclosure UK portal, irrespective of where the recipient of the transfer of value resides.

Multi-Year Contracts

Where a contract for any Transfer of Value runs for more than one year and thus disclosure cycles, Leadiant will disclose Transfers of Value relating to that contract in the year the Transfer of Value was made (which may be different to the year in which the contract was agreed or signed).